STOCK TITAN

GE HealthCare Technologies (GEHC) SEC Filings

GEHC NASDAQ

GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.

The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.

Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) awarded 1,018 restricted stock units and 2,589 employee stock options to Neal Joseph Sandy, its CEO, Patient Care Solutions, on November 16, 2026. Both awards vest or become exercisable in installments of 33% on September 1, 2027, 33% on September 1, 2028, and 34% on September 1, 2029. Each restricted stock unit represents the right to receive one common share; the options have an $82.96 exercise price and expire November 16, 2036. Following the stock award, he held 4,798 common shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) reports that Neal Joseph Sandy, CEO, Patient Care Solutions, had a direct position of 3,780 shares, including restricted stock units. It comprises 1,758 common shares and RSU grants of 775 and 1,247 units; each RSU represents one share at settlement. He also held employee stock options covering 20,000 shares at a $40.4000 exercise price and 13,773 shares at $88.6700. Both option positions are currently exercisable and expire in 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

GE HealthCare Technologies Inc. said Taha Kass-Hout notified the company on November 4, 2026, that he will resign as Chief Science and Technology Officer. His last day at GE HealthCare will be December 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.40%
Tags
current report
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) is named in a Rule 144 notice by former officer James Saccaro proposing a sale of 78,348 common shares, with an aggregate market value of $6,731,613.46 and an approximate sale date of November 4, 2026. The notice lists two stock-option exercise entries, for 54,472 and 23,876 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.40%
Tags
other
-
Rhea-AI Summary

GE HealthCare Technologies Inc. reported third-quarter 2026 revenue of $5.513 billion, compared with $5.143 billion a year earlier, and net income attributable to GE HealthCare of $615 million, versus $446 million. Operating income was $805 million versus $653 million, and diluted earnings per share were $1.36 versus $0.98.

For the nine months ended September 30, 2026, revenue was $15.939 billion versus $14.927 billion, while cash from operating activities was $1.365 billion versus $937 million. Cash, cash equivalents, and restricted cash totaled $2.854 billion as of September 30, 2026, compared with $4.512 billion as of December 31, 2025. The company said the decrease in cash and cash equivalents was primarily due to the Intelerad acquisition. It repurchased 4.7 million shares for approximately $300 million during the nine months.

In the second quarter, GE HealthCare combined its Imaging and Advanced Visualization Solutions businesses into Advanced Imaging Solutions and recast prior segment results. On October 5, 2026, it announced an agreement to acquire SOFIE Biosciences, a U.S.-based contract manufacturing organization for PET radiopharmaceuticals, for $945 million in cash. Closing is expected in the first half of 2027, subject to customary conditions, including regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
quarterly report
-
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) reported third-quarter 2026 revenue of $5.5 billion, up 7.2% year over year, and net income attributable to GE HealthCare of $615 million, versus $446 million. Diluted EPS was $1.36 versus $0.98; adjusted EPS, a non-GAAP measure, was $1.34 versus $1.07. Net income margin was 11.1% versus 8.7%, and adjusted EBIT margin was 16.6% versus 14.8%.

Organic orders grew 4.0%; book-to-bill was 1.03 times and backlog was $23.7 billion. Operating cash flow was $907 million and free cash flow was $793 million, both including a $55 million tariff refund. GE HealthCare raised full-year 2026 guidance to ~4.0% organic revenue growth, 15.5%–15.7% adjusted EBIT margin, $4.95–$5.05 adjusted EPS, and $1.6 billion+ free cash flow. It declared a $0.04 quarterly dividend, 14% above the prior quarter.

GE HealthCare plans to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash, with closing expected in the first half of 2027, subject to customary conditions including regulatory approvals. Jeannette Bankes will leave her President and CEO, Patient Care Solutions role on November 15, 2026; Neal Sandy is to assume the role on November 16, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
current report
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) announced that its Board of Directors has appointed Pascal Desroches to serve as a director, effective January 4, 2027. He will also join the Board’s Audit Committee and the Talent, Culture, and Compensation Committee on that date.

Desroches is Senior Executive Vice President and Chief Financial Officer of AT&T and plans to retire from AT&T on December 31, 2026. He brings more than 30 years of leadership experience in finance, governance, and large-scale technology and digital transformation, including prior roles at WarnerMedia, Turner Broadcasting, KPMG, the U.S. Securities and Exchange Commission, Honeywell Aerospace, the Federal Reserve Bank of Dallas, and DaVita. As a non-employee director, he will receive compensation under GE HealthCare’s existing non-employee director compensation program and will enter into the company’s standard indemnification agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
current report
-
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) reported that its Chief Financial Officer, William K. Grogan, received equity awards on September 14, 2026. He was granted 31,877 employee stock options with an exercise price of $64.25 per share, expiring September 14, 2036, which will become exercisable in three annual installments beginning September 2, 2027.

Grogan also received 62,256 restricted stock units, of which 50% vest on September 14, 2027 and 50% on September 14, 2028, and a separate award of 12,840 restricted stock units vesting 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. Each restricted stock unit represents one share of GE HealthCare common stock at settlement. No Rule 10b5-1 trading plan is reported for these awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.50%
Tags
insider
-
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) had its Chief Financial Officer, William K. Grogan, file an initial statement of beneficial ownership of securities. The filing reports no transactions, no current holdings of company securities, and references an attached power of attorney authorizing filings on his behalf.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.50%
Tags
insider
Rhea-AI Summary

GE HealthCare Technologies Inc. (GEHC) reported that officer Philip Rackliffe, CEO of AIS, had 798 shares of common stock withheld on September 3, 2026 to pay tax withholding obligations triggered by the vesting of restricted stock units. The shares were valued at $70.56 per share for this purpose, and Rackliffe now holds 41,533 shares of GE HealthCare common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
insider

FAQ

How many GE HealthCare Technologies (GEHC) SEC filings are available on StockTitan?

StockTitan tracks 107 SEC filings for GE HealthCare Technologies (GEHC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GE HealthCare Technologies (GEHC)?

The most recent SEC filing for GE HealthCare Technologies (GEHC) was filed on November 18, 2026.